Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Articles|September 3, 2021
Pharmacy Clinical Pearl of the Day: Hypokalemia and Hyperkalemia
Author(s)Saro Arakelians, PharmD
Kidney disease is among the most common causes of both hyperkalemia and hypokalemia.
Advertisement
Clinical Pearl of the Day: Hypokalemia and Hyperkalemia
- Hyperkalemia is high potassium levels.
- Hypokalemia is low potassium levels.
Explanation:
- Normal potassium levels in the body: 3.6- 5.2 (mmol/L).
- Most common causes of hyperkalemia include acute and chronic kidney disease, as well as medications.
- Most common causes of hypokalemia include medication use, such as water pills and kidney disease, as well as alcohol consumption.
- Hyperkalemia treatment options: Patiromer (Veltassa), sodium zirconium (Lokelma)
- Hypokalemia treatment options: Klor-Con, K-Tab, potassium chloride
Reference:
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1c reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
4
Sotatercept in ERS PAH Guidelines: What Pharmacists Should Watch
5